WFRF:(Westman Bo)
Sökning: WFRF:(Westman Bo) > Activation of Akt, ...
LIBRIS Formathandbok (Information om MARC21)
| Fältnamn | Indikatorer | Metadata |
|---|---|---|
| 000 | 04460naa a2200493 4500 | |
| 001 | oai:DiVA.org:liu-88458 | |
| 003 | SwePub | |
| 008 | 130207s2013 | |||||||||||000 ||eng| | |
| 009 | oai:prod.swepub.kib.ki.se:125937544 | |
| 024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-884582 URI |
| 024 | 7 | a https://doi.org/10.1007/s10549-012-2376-y2 DOI |
| 024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1259375442 URI |
| 040 | a (SwePub)liud (SwePub)ki | |
| 041 | a engb eng | |
| 042 | 9 SwePub | |
| 072 | 7 | a ref2 swepub-contenttype |
| 072 | 7 | a art2 swepub-publicationtype |
| 100 | 1 | a Bostner, Josefineu Linköpings universitet,Onkologi,Hälsouniversitetet4 aut0 (Swepub:liu)josbo10 |
| 245 | 1 0 | a Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit |
| 264 | c 2012-12-15 | |
| 264 | 1 | b Springer Verlag (Germany),c 2013 |
| 338 | a print2 rdacarrier | |
| 500 | a Funding Agencies|Swedish Cancer Society||Swedish Research Council||King Gustaf V Jubilee Fund|| | |
| 520 | a The frequent alterations of the PI3K/Akt/mTOR-growth signaling pathway are proposed mechanisms for resistance to endocrine therapy in breast cancer, partly through regulation of estrogen receptor alpha (ER) activity. Reliable biomarkers for treatment prediction are required for improved individualized treatment. We performed a retrospective immunohistochemical analysis of primary tumors from 912 postmenopausal patients with node-negative breast cancer, randomized to either tamoxifen or no adjuvant treatment. Phosphorylated (p) Akt-serine (s) 473, p-mTOR-s2448, and ER phosphorylations-s167 and -s305 were evaluated as potential biomarkers of prognosis and tamoxifen treatment efficacy. High expression of p-mTOR indicated a reduced response to tamoxifen, most pronounced in the ER+/progesterone receptor (PgR) + subgroup (tamoxifen vs. no tamoxifen: hazard ratio (HR), 0.86; 95 % confidence interval (CI), 0.31-2.38; P = 0.78), whereas low p-mTOR expression predicted tamoxifen benefit (HR, 0.29; 95 % CI, 0.18-0.49; P = 0.000002). In addition, nuclear p-Akt-s473 as well as p-ER at -s167 and/or -s305 showed interaction with tamoxifen efficacy with borderline statistical significance. A combination score of positive pathway markers including p-Akt, p-mTOR, and p-ER showed significant association with tamoxifen benefit (test for interaction; P = 0.029). Cross-talk between growth signaling pathways and ER-signaling has been proposed to affect tamoxifen response in hormone receptor-positive breast cancer. The results support this hypothesis, as an overactive pathway was significantly associated with reduced response to tamoxifen. A clinical pre-treatment test for cross-talk markers would be a step toward individualized adjuvant endocrine treatment with or without the addition of PI3K/Akt/mTOR pathway inhibitors. | |
| 653 | a mTOR | |
| 653 | a Akt | |
| 653 | a Estrogen receptor phosphorylation | |
| 653 | a Tamoxifen resistance | |
| 653 | a Immunohistochemistry | |
| 653 | a MEDICINE | |
| 653 | a MEDICIN | |
| 700 | 1 | a Karlsson, Elinu Linköpings universitet,Avdelningen för kliniska vetenskaper,Hälsouniversitetet4 aut0 (Swepub:liu)elika34 |
| 700 | 1 | a Pandiyan, Muneeswaran J.u Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet4 aut |
| 700 | 1 | a Westman, Hannau Linköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet4 aut |
| 700 | 1 | a Skoog, Lambertu Karolinska Institutet4 aut |
| 700 | 1 | a Fornander, Tommyu Karolinska Institutet4 aut |
| 700 | 1 | a Nordenskjöld, Bou Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US4 aut0 (Swepub:liu)bono64 |
| 700 | 1 | a Stål, Olleu Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US4 aut0 (Swepub:liu)ollst87 |
| 710 | 2 | a Linköpings universitetb Onkologi4 org |
| 773 | 0 | t Breast Cancer Research and Treatmentd : Springer Verlag (Germany)g 137:2, s. 397-406q 137:2<397-406x 0167-6806x 1573-7217 |
| 856 | 4 | u https://link.springer.com/content/pdf/10.1007%2Fs10549-012-2376-y.pdf |
| 856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-88458 |
| 856 | 4 8 | u https://doi.org/10.1007/s10549-012-2376-y |
| 856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:125937544 |
Hitta via bibliotek
- Breast Cancer Research and Treatment (Sök värdpublikationen i LIBRIS)
Till lärosätets databas
Hitta mer i SwePub
- Av författaren/redakt...
- Bostner, Josefin ...
- Karlsson, Elin
- Pandiyan, Munees ...
- Westman, Hanna
- Skoog, Lambert
- Fornander, Tommy
- visa fler...
- Nordenskjöld, Bo
- Stål, Olle
- visa färre...
- Artiklar i publikationen
- Breast Cancer Re ...
- Av lärosätet
- Linköpings universitet
- Karolinska Institutet
Sök utanför SwePub
- Sök vidare i:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - Nationella bibliotekssystem
- LIBRIS.kb.se
